At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Term pregnancy 37–42 weeks
- ✓ASA Physical Status II or III
- ✓Scheduled for elective cesarean delivery
- ✕≥3 prior cesarean deliveries
- ✕Pre-pregnancy BMI >40 kg/m²
- ✕Planned concurrent surgical procedure other than tubal ligation
- ✕Chronic pain or chronic opioid therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Erector Spinae Plane Block With Liposomal Bupivacaine for Post Cesarean Delivery Analgesia: A Pilot Study
In Brief
A Phase 4 clinical trial evaluating Erector Spinae Plane (ESP) Block, bupivacaine liposome injectable suspension, and 1 other intervention for Cesarean Section Complications. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The purpose of this pilot study is to assess the analgesic efficacy of Erector Spinae Plane block (ESPB) with liposomal bupivacaine in women undergoing cesarean delivery and receiving a postoperative multimodal analgesic regimen as assessed by the dose of rescue postoperative opioids compared to a historical control group of women receiving the same multimodal regimen but with no truncal blocks. This will be a case control study with a prospective and a retrospective component. Women undergoing elective cesarean delivery under spinal or combined spinal epidural anesthesia will be approached to participate in the prospective open label component of the study. Cases will be matched in a 1:4 ratio by age, race, history of prior cesarean delivery, and insurance status with historical controls who received the same multimodal analgesic regimen but no truncal blocks. We plan to enroll 30 subjects for the prospective arm of the study and 120 for the retrospective arm.
Study Details
Timeline
Interventions
ESP Block with liposomal bupivacaine and immediate release bupivacaine
133 mg liposomal bupivacaine per side.
20 ml bupivacaine 0.25% per side.